Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01851551 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
A Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT01851551 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma that has completed, run by Acrotech Biopharma. The registered enrollment target is 22 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01851551, a Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
This was a Phase 1/2 study performed at two clinical centers in the US and UK. It was a single arm, open label study evaluating VSLI plus rituximab in adults with aggressive relapsed or refractory non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG Vincristine Sulfate Liposome Injection plus rituximab
Study Locations (2)
California
- University of California - San Francisco
West Yorkshire
- Leeds General Infirmary - Leeds
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2001-09 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01851551
The ClinicalTrials.gov registry entry for NCT01851551 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Vincristine Sulfate Liposome Injection plus rituximab is the first listed.
NCT01851551 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, West Yorkshire.
Frequently Asked Questions
What is clinical trial NCT01851551 about?
NCT01851551 is a clinical study titled "Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL". This was a Phase 1/2 study performed at two clinical centers in the US and UK. It was a single arm, open label study evaluating VSLI plus rituximab in adults with aggressive relapsed or refractory non-Hodgkin's lymphoma.
What is the current status of trial NCT01851551?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2001-09. Estimated completion is 2005-04.
What conditions does trial NCT01851551 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01851551?
The interventions under investigation include: Vincristine Sulfate Liposome Injection plus rituximab (DRUG).
Who is sponsoring clinical trial NCT01851551?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01851551 being conducted?
This trial has 2 study locations across California, West Yorkshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.